Clinical trials: Drug Eluting Stents
Coronary Artery Disease
E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent
The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis.
- Trial name
- eFive (NCT00623441)
- Testing
- Endeavor Zotarolimus Eluting Coronary Stent
- Volunteers
- 8,314 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Artery Disease, Coronary Artery Stenosis
Absorb IV Randomized Controlled Trial
ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind, multi-center study, registering approximately 2610 subjects from approximately 140 sites in the United States and outside the United States.
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- NCT02173379
- Testing
- Absorb BVS, XIENCE
- Where
- 120 sites in United States, Australia and 3 more
- Volunteers
- 2,604 people
- Sponsor
- Abbott Medical Devices
Angina, Stable, Acute Coronary Syndrome
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or *3 allele and ticagrelor in carriers of a CYP2C19*2 or…
- Conditions
- Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents, Genotype
- Trial name
- NCT03783351
- Testing
- CYP2C19 genotype testing
- Where
- 9 sites in China
- Volunteers
- 4,009 people
- Sponsor
- Beijing Anzhen Hospital
Coronary Artery Disease
The ELUTES Clinical Trial
ELUTES is a European multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the Paclitaxel Eluting V-Flex Plus coronary stent to reduce restenosis in the coronary artery.
- Trial name
- ELUTES I (NCT00225654)
- Testing
- coronary stent
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Cook Group Incorporated
Coronary Disease
Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD
This study is to compare clinical outcomes between quantitative coronary angiography-guided anatomic complete revascularization and fractional flow reserve-guided physiologic complete revascularization in patients with…
- Trial name
- ASSIST (NCT05529459)
- Testing
- Percutaneous Coronary Intervention
- Where
- 17 sites in South Korea
- Volunteers
- 2,400 people
- Sponsor
- Seung-Whan Lee, M.D., Ph.D.
Coronary Arteriosclerosis, Acute Coronary Syndrome
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
- Trial name
- GRAVITAS (NCT00645918)
- Testing
- clopidogrel
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Accumetrics, Inc.
Late Acquired Stent Malaposition
Late Acquired Malaposition and Different Polymers
The polymers releasing the drug of first-generation drug-eluting stents (DES) may induce allergic reactions and inflammation, resulting in late-acquired stent malaposition (LASM) with uncoverage of struts, and risk of stent…
- Trial name
- NCT02018991
- Testing
- Everolimus-Eluting Stent (EES), Zotarolimus-Eluting-Stent (ZES), Biolimus-Eluting-Stent (BES)
- Where
- Austria
- Volunteers
- 69 people
- Sponsor
- Medical University of Vienna
Coronary Artery Disease
Biomime Stent in All-comers PCI Patients Registry
Biomime stent is a novel sirolimus-eluting stent (SES) (Meril Life Sciences Pvt. Ltd., Gujarat, India) with an ultra-thin stent platform (65 μm) and a biodegradable polymer licensed for the treatment of de novo coronary lesions.
- Trial name
- BELLINI (NCT02398955)
- Testing
- percutaneous coronary intervention
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Coronary Artery Disease
COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1)
This First In Man study is a prospective, multicentre, single blind, randomized, controlled clinical trial of the CINATRA™ ISA 247 Coated Coronary Stent System as compared to the CINATRA™ Coronary Stent System.
- Trial name
- CONFIRM 1 (NCT00689767)
- Testing
- CINATRA™ Coronary Stent System, CINATRA™ ISA 247 Coated Coronary Stent System
- Where
- 7 sites in Belgium
- Volunteers
- 103 people
- Sponsor
- Atrium Medical Corporation
Diffuse Coronary Artery Lesions
Comparison of Safety and Efficacy of Coronary Drug-coated Balloon (DCB) Combined With Spot Stenting of Drug-eluting Stent (DES) Versus Second-generation DES for Treating Diffuse Coronary Artery Lesions: a Prospective, Randomized, Controlled Clinical Trial
The prospective, randomized, controlled clinical trial aims to evaluate the safety and efficacy of paclitaxel-eluting PTCA-balloon catheter (SeQuent® Please) combined with provisional spot stenting of DES versus DES for treating…
- Trial name
- NCT03589157
- Testing
- drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES), drug-coated balloon (DCB) combined with second-generation of drug-eluting stent (DES)
- Volunteers
- 140 people
- Sponsor
- Chinese PLA General Hospital
Coronary Artery Disease
"JACTAX" Trial Drug Eluting Stent Trial
Prospective, multi-center, non-randomized registry. 100 patients will be enrolled at up to 10 clinical sites in Europe. The results of this study will be compared to the TAXUS™ ATLAS clinical trial to evaluate the safety of the…
- Trial name
- NCT00754728
- Testing
- JACTAX DES
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Boston Scientific Corporation
In-stent Restenosis
Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)
To demonstrate acceptable short term safety rates of the Drug-eluting Coronary Spur Stent System as a primary treatment for coronary in-stent restenosis.
- Trial name
- NCT06117150
- Testing
- Drug-eluting Coronary Spur Stent System
- Where
- 2 sites in New Zealand
- Volunteers
- 9 people
- Sponsor
- ReFlow Medical, Inc.
Coronary Artery Disease
ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CAD
Prospective, multi-center, open-label single-arm study designed to enroll 85 patients in up to 15 centers in up to 3 European countries. All patients will be followed up for 9 months.
- Trial name
- NCT05799963
- Testing
- BioMatrix Alpha
- Where
- 9 sites in Germany, United Kingdom
- Volunteers
- 85 people
- Sponsor
- Biosensors Europe SA
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease, Atherosclerosis
Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents
The purpose of this study is to compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstriction in…
- Trial name
- ASSESS (NCT01073111)
- Testing
- zotarolimus-eluting stent (ENDEAVOR®), sirolimus-eluting stents (CYPHER SELECT® PLUS), everolimus-eluting stents (PROMUS®)
- Where
- Japan
- Sponsor
- Hyogo Medical University
Coronary Artery Disease, Drug-eluting Stents
Safety and Efficacy of the Ultimaster Stent
Durable polymer was considered to be the cause of a chronic inflammatory response that leadas to impaired endothelialization of the stent strut and subsequently increases the risk of stent thrombosis.
- Trial name
- NCT05677711
- Testing
- ultimaster
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Ischemic Heart Disease
Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent
The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the sirolimus eluting ORSIRO stent and the biolimus-eluting NOBORI stent in a population-based…
- Trial name
- SORT OUT VII (NCT01879358)
- Testing
- Drug-eluting stent
- Where
- Denmark
- Volunteers
- 2,314 people
- Sponsor
- Odense University Hospital
Drug-eluting Stents, Percutaneous Coronary Intervention
In-stent Repair and Vessel Reaction of STEMI Patients With OCT
This study is a prospective, multi-center, non-inferior, randomized controlled clinical trial, aims to use optical Coherence tomography to observe the the early- and mid-stage vessel repair and neointimal proliferation.
- Conditions
- Drug-eluting Stents, Percutaneous Coronary Intervention, Optical Coherence Tomography, ST-Elevation Myocardial Infarction
- Trial name
- NCT04150016
- Testing
- percutaneous coronary intervention
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Xijing Hospital
Acute Coronary Syndrome, Lipid Disorder
Polypill in Acute Coronary Syndrome
Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and healthcare costs. Effective therapies are widely available; however, adherence is low.
- Conditions
- Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
- Trial name
- POLY-ACS (NCT05514938)
- Testing
- Polypill, Usual Care (individual medications prescribed by primary cardiologist)
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Texas Southwestern Medical Center
Coronary Artery Disease
A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT
1. Prospective, randomized, multicenter clinical study 2. This is a post-marketing clinical study to evaluate whether it will affect the safety event when it is used in different treatment ways.
- Trial name
- NCT03716011
- Testing
- EXCROSSAL
- Where
- China
- Volunteers
- 2,700 people
- Sponsor
- JW Medical Systems Ltd